GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Charles River Laboratories International CRL · USD

Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States

S&P 500

Compare

353.34

+4.69%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

22 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 7Strong buy
  • 10Buy
  • 5Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Average target 267.60

Low
219.00
Average
267.60
Median
273.00
High
300.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$3.92bn$4.01bn$4.25bn$4.52bn$4.79bn
Revenue, highest$3.93bn$4.09bn$4.37bn$4.59bn$4.87bn
Revenue, lowest$3.91bn$3.95bn$4.09bn$4.45bn$4.72bn
Earnings per share11.3812.8014.3316.4317.65
Earnings per share, highest11.5113.0617.8416.7818.03
Earnings per share, lowest11.2012.1010.1716.1117.31
Analysts101212610

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast2.972.741.962.372.362.522.102.56
Reported3.093.022.062.392.433.122.342.66
Difference+4.0%+10.2%+5.0%+1.0%+2.9%+23.7%+11.4%+4.0%

Rating changes

Latest broker notes

  • TD CowenBuy
  • Morgan StanleyOverweight
  • RBC CapitalOutperform
  • JP MorganNeutral → Overweight
  • Evercore ISI GroupOutperform
  • CLSAOutperform → Hold
  • MizuhoNeutral
  • Morgan StanleyOverweight
  • Morgan StanleyEqual Weight → Overweight
  • CLSAHold → Outperform
  • Evercore ISI GroupOutperform
  • BarclaysOverweight

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth 11.4% a year over 10 years. Return on equity -4.6%.

Model fair value

6,422.86

From earnings 6,422.86, from revenue 195.74.

Piotroski score

3 / 9

A nine-point test of financial strength, for 27 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.